Dear Ms Grevfors-Ernoult,

On behalf of the undersigned organisations, we wished to communicate with you in respect to the matter of cytotoxic safety, especially in the context of the present revision of the carcinogens and mutagens directive. We write to communicate 3 key points, as well as request an in-person meeting at which we might expand upon these and have open dialogue. Our 3 points are:

1. **Cytotoxic safety is a real and present occupational health concern for hospital workers and patients across Europe, deserving of further national and pan-national attention;**

The undersigned organisations therefore support attention to the matter of cytotoxic safety in the context of the present legislative deliberations on the carcinogens and mutagens directive. The opportunity to take action at an EU level on this issue offers an important chance to improve hospital worker and patient safety in all member states. We therefore wish to open further dialogue with you about this.

2. **The available solutions to improve cytotoxic safety are multi-dimensional, and should be understood as such by policy makers**

Means of better addressing cytotoxic safety include:

a) heightened awareness by healthcare professionals, patients, health system managers and political decision-makers;
b) improved education;
c) well written and implemented working procedures; as well as,
d) adoption of technological solutions, where strong independent evidence can support its uptake.

The undersigned societies urge that Commission activity aimed towards addressing cytotoxic safety reflect **all** of these areas for potential improvement, rather than take any individual area in isolation.

3. **Further independent and well-funded studies and investigations are required**

One of the most powerful forms of assistance that the Commission could provide in respect to addressing cytotoxic safety concerns across Europe would be to facilitate the conduct of independent and well-resourced research into the best available means for achieving improvement. Such research could provide a better evidence base as to whether further guidance or regulation is required at national or European levels. We would welcome a meeting with you to consider how such studies could be realised, by whom, their scope and timescales.

I hope you will not mind me following up with your office about the possibility of a meeting between a delegation of the undersigned organisations and your unit in the near future.

Yours sincerely,

R. Price

Prof. Klaus Meier, President of the European Society of Oncology Pharmacists (ESOP), President of the German Society for Oncology Pharmacy, Chair of the European CanCer Organisation (ECCO) Oncopolicy Committee.

Supported by: the European CanCer Organisation (ECCO); the European Society of Oncology Pharmacy; the European Oncology Nursing Society (EONS); the European Society for Paediatric Oncology (SIOPE); and, the European Association of Hospital Pharmacists (EAHP).